Current concepts in asthma treatment in children

Current Opinion in Pediatrics

Volumn 16, Issue 3, 2004, Pages 299-304

  Szefler, Stanley J ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Asthma pharmacotherapy; Childhood asthma; Corticosteroids; Immunomodulators; Leukotriene receptor antagonists

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MONTELUKAST; OMALIZUMAB; PREDNISOLONE; SALBUTAMOL; SALMETEROL;

ASTHMA; CHILDHOOD DISEASE; CLINICAL PROTOCOL; EARLY DIAGNOSIS; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALLERGENS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ENVIRONMENTAL EXPOSURE; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 2542491228     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000125069.73952.a4     Document Type: Review

References (50)

1. National Asthma Education and Prevention Program Report: Guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002, 110:S141-S219.
2. Mannino DM, Homa DM, Akinbami LJ, et al.: Surveillance for asthma-United States, 1980-1999. MMWR Morbid Mortal Wkly Rep 2002, 51:1-13.
3. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. NIH publication 02-3659. Bethesda: National Heart, Lung, and Blood Institute, National Institutes of Health; 2002. Also available at www.ginasthma.com.
4. Busse WW, Lenfant C, Lemanske RF: Asthma guidelines: a changing paradigm to improve asthma care. J Allergy Clin Immunol 2002, 110:703-705.
5. Szefler SJ, Eigen H: Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002, 109:730-742.
6. Knorr B, Franchi LM, Bisgaard H, et al.: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001, 108:1-10.
7. Leflein JG, Szefler SJ, Murphy KR, et al.: Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcome trial. Pediatrics 2002, 109:866-872.
8. Szefler SJ: New directions in asthma therapy. In Pediatric Allergy: Principles and Practice. Edited by Leung DYM, Sampson H, Geha R, et al. St. Louis: Mosby; 2003:465-472. This is a recent review of the future directions that hold promise for improving asthma management in children.
9. Suissa S, Ernst P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937-944.
10. The Childhood Asthma Management Program Research Group: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054-1063.
11. Milgrom H, Skoner DP, Bensch G, et al.: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001, 108:938-945.
12. Carl JC, Myers TR, Kirchner HL, et al.: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003, 143:731-736. This is a report on the efficacy of levalbuterol in reducing hospitalizations for acute exacerbations compared with racemic albuterol when applied in the emergency care setting.
13. Matz J, Emmett A, Rickard K, et al.: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001, 107:783-789.
14. Aalbers R, Backer V, Kava TTK, et al.: Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004, 20:225-240. This is a report of a new approach to using combination therapy of an ICS and a long-acting β-adrenergic agonist as maintenance therapy with increased doses as needed to control acute symptoins. This approach addresses the variable course of asthma and shows reduced exacerbations with the adjustable dose approach.
15. Fitzgerald JM, Sears MR, Boulet L-P, et al.: Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003, 10:427-434. Similar to the previous report, this study also supports the efficacy of the adjustable dosing strategy with combination therapy in reducing asthma exacerbations.
16. Stafford RS, Ma J, Finkelstein SN, et al.: National trends in asthma visits and asthma pharmacotherapy, 1978-2002. J Allergy Clin Immunol 2003, 111:729-735. This study evaluated the use of an evidence-based guidelines approach for asthma outcomes in a health care setting.
17. Lai CKW, de Guia TS, Kim Y-Y, et al.: Asthma control in the Asia-Pacific region: the asthma insights and reality in Asia-Pacific study. J Allergy Clin Immunol 2003, 111:263-268.
18. Jenkins HA, Cool C, Szefler S, et al.: Histopathology of severe childhood asthma: a case series. Chest 2003, 124:32-41. There is currently very little information on the pathology of severe asthma. This publication is unique in that it specifically reports the pathology of severe asthma in children.
19. Marotta A, Klinnert MD, Price MR, et al.: Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma. J Allergy Clin Immunol 2003, 112:317-322. Measurement of standard pulmonary function via spirometry is not feasible in young children. New techniques must be developed that will facilitate obtaining measures of pulmonary function in young children. This publication provides some insight into the potential use of forced oscillation, a technique that requires minimal cooperation from a young child, to follow pulmonary function in young children.
20. Brussee JE, Smit HA, Koopman LP, et al.: Interrupter resistance and wheezing phenotypes at 4 years of age. Am J Respir Crit Care Med 2004, 169:209-213. This study reports on measurements of airway resistance as a measure of airway obstruction in children who go on to have persistent wheeze.
21. Anderson SD, Fitch K, Perry CP, et al.: Responses to bronchial challenge submitted for approval to use inhaled β2-agonists before an event at the 2002 Winter Olympics. J Allergy Clin Immunol 2003, 111:45-50. Although there is a significant amount of information regarding the management of exercise-induced asthma, there is almost no information on exercise-induced asthma in the competitive athlete. This publication provides insight into the unique features of managing this complication of asthma in this unique population.
22. Strunk RC, Szefler SJ, Phillips BR, et al.: Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003, 112:883-892. The application of biomarkers is a new and exciting direction for the management of asthma. This publication provides some new insight that a biomarker such as exhaled nitric oxide may provide in relation to asthma control measures.
23. Allen DB, Bielory L, Derendorf H, et al.: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003, 112:S1-S40. This publication is a comprehensive summary of the potential risk of current ICS. Although these medications are deemed very safe, this review group suggests there is some room for improvement.
24. Leone FT, Fish JE, Szefler SJ, et al.: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma. Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003, 124:2329-2340. This is a comprehensive, evidence-based review of the literature related to adverse effects of ICS therapy for asthma. Available evidence is graded and interpreted for application to clinical practice.
25. Pauwels RA, Pedersen S, Busse WW, et al.: Early intervention with budesonide in mild persistent asthma. Lancet 2003, 361:1071-1076. This is a comprehensive, large, worldwide study on the effects of early intervention with ICS in children and adults with mild persistent asthma.
26. Sullivan SD, Buxton M, Anderson LF, et al.: Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003, 112:1229-1236.
27. Schatz M, Cook EF, Nakahiro R, et al.: Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immunol 2003, 111:503-508.
28. Busse W, Koenig SM, Oppenheimer J, et al.: Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. J Allergy Clin Immunol 2003, 111:57-65. This study documents the steroid-sparing effect of combination therapy with an ICS and a long-acting β-adrenergic agonist.
29. Nelson HS, Chapman KR, Pyke SD, et al.: Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003, 112:29-36.
30. Calhoun WJ, Sutton LB, Emmett A, et al.: Asthma variability in patients previously treated with β2-agonists alone. J Allergy Clin Immunol 2003, 122:1088-1094. This report documents the considerable variability in asthma presentation within individual patients that can occur over an observed period of time.
31. Wong J, Davies T, O'Callaghan C: Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: effect on urinary cortisol excretion. J Allergy Clin Immunol 2002, 110:721-727.
32. Hayden JT, Smith N, Woolf DA, et al.: A randomized crossover trial of face mask efficacy. Arch Dis Child 2004, 89:72-73. This study points to the variability in delivered medication from a metered dose inhaler that can be influenced by the simple step of adding different face masks.
33. Israel E, Chervinsky PS, Friedman B, et al.: Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002, 110:847-854.
34. Meyer KA, Arduino JM, Santanello NC, et al.: Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 2003, 111:757-762.
35. Melo RE, Solé D, Naspitz CK: Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003, 111:301-307. This study demonstrates the effect of a leukotriene receptor antagonist on attenuating the drop in pulmonary function that can occur after exercise in children with asthma.
36. Corren J, Casale T, Deniz Y, et al.: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003, 111:87-90. There is significant interest in the potential application of a newly approved asthma medication, omalizumab, or anti-IgE. This publication summarizes observations related to the reduction of asthma exacerbations after the use of this medication.
37. Finn A, Gross G, van Bavel J, et al.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003, 111:278-284.
38. Csonka P, Kaila M, Laippala P, et al.: Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr 2003, 143:725-730. This study reports the beneficial effects of a short course of oral corticosteroid therapy in young children with viral-induced lower respiratory episodes.
39. Sears MR, Greene JM, Willan AR, et al.: A longitudinal, population-based cohort study of childhood asthma followed to adulthood. N Engl J Med 2003, 349:1414-1422. This very recent publication attempts to identify asthma phenotypes that define the natural history of asthma. It also identifies risk features for the persistence of asthma from childhood to adulthood.
40. Chulada PC, Arbes SJ Jr, Dunson D, et al.: Breast-feeding and the prevalence of asthma and wheeze in children: analyses from the Third National Health and Nutrition Examination Survey, 1988-1994. J Allergy Clin Immunol 2003, 111:328-336.
41. Oddy WH, Halonen M, Martinez FD, et al.: Transforming growth factor beta in human milk is associated with wheeze in infancy. J Allergy Clin Immunol 2003, 112:723-728.
42. Dunstan JA, Mori TA, Barden A, et al.: Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol 2003, 112:1178-1184. This is an early report of the effect of dietary intervention during pregnancy to reduce infant allergy.
43. Rullo VEV, Rizzo MC, Arruda LK, et al.: Daycare centers and schools as sources of exposure to mites, cockroach, and endotoxin in the city of São Paulo, Brazil. J Allergy Clin Immunol 2002, 110:582-588.
44. Werner M, Topp R, Wimmer K, et al.: TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003, 112:323-330.
45. Litonjua AA, Milton DK, Celedon JC, et al.: A longitudinal analysis of wheezing in young children: the independent effects of early life exposure to house dust endotoxin, allergens, and pets. J Allergy Clin Immunol 2002, 110:736-742.
46. Svanes C, Heinrich J, Jarvis D, et al.: Pet-keeping in childhood and adult asthma and hay fever. European Community Respiratory Health Survey. J Allergy Clin Immunol 2003, 112:289-300.
47. Medeiros M, Figueiredo JP, Almeida MC, et al.: Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol 2003, 111:947-951.
48. Kotaniemi-Syrjänen A, Vainionpää R, Reijonen TM, et al.: Rhinovirus-induced wheezing in infancy - the first sign of childhood asthma? J Allergy Clin Immunol 2003, 111:66-71. This study evaluates the impact of rhinovirus on wheezing in infancy.
49. Kim CK, Kim SW, Park CS, et al.: Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J Allergy Clin Immunol 2003, 112:64-71.
50. Bager P, Westergaard T, Rostgaard K, et al.: Smallpox vaccination and risk of allergy and asthma. J Allergy Clin Immunol 2003, 111:1227-1231.